Contribution of CSF biomarkers to early-onset Alzheimer’s disease and frontotemporal dementia neuroimaging signatures

Neus Falgàs1,2 | Mariona Ruiz-Peris1,3 | Agnès Pérez-Millan1,3 | Roser Sala-Llonch3 | Anna Antonell1 | Mircea Balasa1,5 | Sergi Borrego-Écija1 | Oscar Ramos-Campoy1 | Josep Maria Augé4 | Magdalena Castellví1 | Adrià Tort-Merino1 | Jaume Olives1 | Guadalupe Fernández-Villullas1 | Kaj Blennow6,7 | Henrik Zetterberg6,7,8,9 | Núria Bargalló10 | Albert Lladó1 | Raquel Sánchez-Valle5

1Alzheimer’s Disease and Other Cognitive Disorders Unit, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Fundació Clínic per a la Recerca Biomèdica, University of Barcelona, Barcelona, Spain
2Atlantic Fellow for Equity in Brain Health, Global Brain Health Institute, University of California, San Francisco, California
3Department of Biomedicine, University of Barcelona, Barcelona, Spain
4Biochemistry and Molecular Genetics Department, Hospital Clinic de Barcelona, Barcelona, Spain
5Senior Atlantic Fellow for Equity in Brain Health, Global Brain Health Institute, Trinity College Dublin, Ireland
6Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
7Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
8Department of Neurodegenerative Disease, University College London, London, UK
9UK Dementia Research Institute at UCL, London, UK
10Radiology Service, Hospital Clinic, MRI imaging platform. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

Correspondence
Raquel Sánchez-Valle, MD, PhD, Alzheimer’s Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic IDIBAPS, University of Barcelona, Villarroel, 170, Barcelona 08036, Spain.
Email: rsanchez@clinic.cat

Funding information
Forskningsrådet om Hälsa, Arbetsliv och Välfärd, Grant/Award Number: 20143810; Generalitat de Catalunya, Grant/Award Numbers: SLT002/16/00408, SLT008/18/00061, SLT002/16/00329; European Research Council, Grant/Award Number: 681712; Hjärnfonden, Grant/Award Number: FO2017-0243; Hospital Clinic Barcelona; Spanish Ministry of Economy and Competitiveness, Grant/Award Number:...
Early-onset dementia (EOD) is usually defined by a clinical onset under 65 and can reach up to the 5–10% of patients with dementia. Alzheimer’s disease (AD) is the most common cause of EOD, followed by frontotemporal lobar degeneration (FTLD; Garre-Olmo, Genis Batlle, del Mar Fernández, et al., 2010). Early-onset AD (EOAD) is characterized by a faster disease progression and atypical presentations (nonamnestic symptoms) overlapping with other neurodegenerative dementias such as FTLD making the diagnosis more challenging (Koedam, Lauffer, van der Vlies, et al., 2010; Wattmo & Wallin, 2017). Thus, the use of neuroimaging and biochemical biomarkers is especially suitable in EOD in order to establish an early and accurate diagnosis (Falgàs, Tort-Merino, Balasa, et al., 2019).

Several studies have aimed to determine the different profiles of cerebrospinal fluid (CSF) biomarkers in different neurodegenerative diseases such as AD or FTLD (Blennow & Zetterberg, 2018). Some of these biomarker profiles have been well described while other novel biomarkers are still under investigation. Decreased amyloid-beta protein 42 (Aβ42) with increased total tau (T-tau) and phosphorylated tau (P-tau) levels define the typical AD biochemical profile (Albert, DeKosky, Dickson, et al., 2011; Mattson, 2017; McKhann, Knopman, Chertkow, et al., 2011) Regarding novel biomarkers, neurofilament light chain (NfL) has been proposed as a nonspecific neurodegeneration marker. Increased levels of NfL have been reported in FTLD, as well as in AD and other neurodegenerative disorders (i.e., amyotrophic lateral sclerosis or multiple sclerosis). CSF NfL levels have proved especially useful differentiating FTLD from early-onset AD given that NfL levels in AD are lower in early onset compared to those in late onset presentations (Alcolea, Vilaplana, Suárez-Calvet, et al., 2017; Olsson, Portelius, Cullen, et al., 2019; Portelius et al., 2018; Sjögren, Rosengren, Minthon, et al., 2000). Neurogranin (Ng) is a synaptic (dendritic) marker that has been suggested to be specific for AD although increased levels are also found in Creutzfeldt–Jakob diseases (Blennow, Diaz-Lucena, Zetterberg, et al., 2019; Gaetani, Blennow, Calabresi, et al., 2019; Wellington et al., 2016). The 14-3-3 protein has been extensively studied in Creutzfeldt–Jakob disease, but its participation on the AD neuro-pathological process has also been described (Burkhard, Sanchez, Landis, et al., 2001; Chohan et al., 2010; McFerrin, Chi, Cutter, et al., 2017). Furthermore, previous studies have suggested that some of these biomarkers, as NfL or Ng, could provide information about the disease prognosis in AD and FTLD, respectively (Ljubenkov et al., 2018; Rohrer et al., 2016; Scherling et al., 2014).

Neuroimaging using Magnetic Resonance Imaging (MRI) has been widely used to describe cortical thickness (CTh) and white matter (WM) loss patterns in AD and FTLD as well as to find differential trajectories along the different disease stages (Canu et al., 2017; Möller, Hafkemeijer, Pijnenburg, et al., 2015; Moreno et al., 2013; Sala-Llonch et al., 2015). The relationship between AD neuroimaging features and classical AD biochemical markers and their reciprocal influence have been studied during both the clinical and preclinical phases of the disease (Sala-Llonch et al., 2015). However, studying the influence of new biomarkers is more challenging as the trajectories have been poorly described and they might interact with those already reported, possibly giving nontrivial relationships. In this sense, how the different CSF biomarkers might explain or contribute to each disease atrophy pattern is still uncertain (Idland et al., 2017; Pugueroles, 2017).

In this context, our goals were (a) to provide a descriptive analysis of CSF-biomarker levels and structural patterns (CTh, hippocampal volume, and FA) in early-onset AD and FTLD, (b) to study the relationship between early-onset AD and FTLD brain structural measures and CSF-biomarkers levels, and (c) to perform a multivariate approach to evaluate which biomarkers better explained the characteristic structural alterations associated with each disease (i.e., disease signatures).

## 2 | MATERIALS AND METHODS

### 2.1 | Participants

One hundred thirty-eight subjects with disease onset under 65 were evaluated at the Alzheimer’s Disease and Other Cognitive Disorders Unit at Hospital Clinic de Barcelona and were enrolled on this cross-sectional study from 2009 to 2016. All subjects underwent a complete neurological and neuropsychological evaluation, 3T brain MRI...
scan and a spinal tap for the determination of CSF biomarkers. Subjects were classified into three groups:

- **AD group (n = 64):** All EOAD patients fulfilled the National Institute on Aging-Alzheimer’s Association (NIA-AA) diagnostic criteria for MCI due to AD or mild AD dementia and Mini-Mental State Examination (MMSE) ≥18 (Albert et al., 2011; McKhann et al., 2011). All subjects had a typical AD CSF biomarker pattern. Both early sporadic AD (n = 52) and autosomal dominant AD (ADAD) (n = 12) were included.

- **FTD group (n = 26):** Ten behavioral variant of FTD (bvFTD) patients, eight nonfluent variant for primary progressive aphasia (nvPPA) and eight semantic variant of primary progressive aphasia (svPPA) patients were included Rascovsky et al., 2011; Gorno-Tempini et al., 2011. Ten cases were genetic cases (four carried the C9ORF72 expansion, two MAPT mutations, and four GRN mutations). All FTLD were at mild phases of the disease (MMSE ≥18) at inclusion.

- **Healthy controls (CTR) (n = 48):** healthy adults (age < 65 years old) with no cognitive complaints, cognitive performance within normative range and normal levels of AD CSF biomarkers.

The study was approved by the Hospital Clinic Barcelona Ethics Committee and all participants gave written informed consent.

### 2.2 | CSF biomarkers

- Commercially available single-analyte enzyme-linked immunosorbent assay (ELISA) kits were used to determine levels of CSF Ab42, T-tau and P-tau (INNOTEST, Fujirebio Europe N.V., Gent, Belgium), NfL (IBL International, Hamburg, Germany) and 14-3-3 (CircuLex, MBL International Corporation, Woburn, MA) at the Alzheimer’s Disease and Other Cognitive Disorders Unit Laboratory, Barcelona. The following CSF cut-off values were used in order to classify the subjects to NIA-A criteria as amyloid positive 550 pg/ml (CSF samples measured before February 2016) and 750 pg/ml (for those measured after February 2016, due to changes in the commercial kits), or neuronal injury positive (T-tau >385 pg/ml and/or P-tau 65 pg/ml). Cut-offs were obtained based on internal controls. CSF Ng concentration was measured using an in-house ELISA based on the monoclonal antibody Ng7 (epitope including amino acids 52–65 on Ng) at the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden (Kvartsberg et al., 2015; Willemse, De Vos, Herries, et al., 2018). The intracoefﬁcient variation (CV) was 0.5–3% and the inter-CV 5–8% for NfL. Ng and 14-3-3 biomarkers. All 138 participants had CSF Ab42, T-tau, and P-tau levels available. NfL levels were available in 133 subjects, Ng in 104, and 14-3-3 in 94.

### 2.3 | MRI acquisition

All participants were examined in the same 3T MRI scanner (Magnetom Trio Tim, Siemens Medical Systems, Germany). A high-resolution 3D structural data set (T1-weighted, MP-RAGE, repetition time = 2,300 ms, echo time = 2.98 ms, 240 slices, field-of-view = 256 mm, voxel size = 1 × 1 × 1 mm) and a diffusion weighted echo-planar imaging (EPI) sequence (30 directions + b0 image, with two repeated acquisitions, TR = 7,600 ms, TE = 89 ms, 60 slices, distance factor = 0%, FOV = 250 mm, matrix size =122 × 122, voxel size = 2 × 2 × 2 mm) were acquired for all subjects.

### 2.4 | Statistical analysis of demographics and CSF-biomarkers levels

We first obtained group descriptive data using the median and interquantile range for each CSF biomarker within each group. Shapiro-Wilk test for normality were done for each diagnostic group. Group comparisons were analyzed using chi-square for gender or Kruskall–Wallis tests for the rest of the variables. The significance threshold was set at a Bonferroni corrected p level of .05 to adjust for multiple comparisons (corrected p threshold = .0018).

Additionally, we performed additional analyses in order to compare the subgroup of bvFTD subjects (N = 10) with the rest of the FTLD patients. These were done also through Kruskall–Wallis tests.

### 2.5 | Cortical thickness processing and analysis

CTh processing and vertex-wise analyses were performed using FreeSurfer v6.0.0 (https://surfer.nmr.mgh.harvard.edu/). The entire pipeline is fully explained elsewhere and includes a set of methods applied to the T1-weighted MRI images to generate brain surfaces and CTh maps, calculated as the closest distance between the gray/WM surface to the pial surface at each vertex of the tesselated surface (Dale, Fischl, & Sereno, 1999; Fischl & Dale, 2000). Before statistics, individual CTh maps were registered to a common space and smoothed using a FWHM of 15 mm.

Using the vertex-wise CTh data, we performed a set of analyses using general linear models (GLMs). We first evaluated group differences, using age as covariate. Then, for each biomarker, we computed the correlation between the biomarker levels and CTh within each group. Results were corrected for multiple comparisons using Monte-Carlo simulations, and setting a threshold of p < .05 for cluster significance.

### 2.6 | Hippocampal volumes

Since the hippocampus is the main subcortical structure affected in AD we also assessed the hippocampal volume. We used the automated segmentation from FreeSurfer to obtain measures of hippocampal volume (Fischl et al., 2002). We calculated normalized hippocampal volume for each subject, by averaging left and right hippocampi and dividing by the total intracranial volume. We then calculated group differences and correlations with biomarker levels in hippocampal volume in R (https://www.r-project.org/)
2.7 | DTI processing and analysis

DTI processing and voxel-wise statistical analyses were performed with FSL v5.0.11 (https://fsl.fmrib.ox.ac.uk/fsl). Diffusion weighted images were first registered, using the B0 image as a reference volume, and corrected for motion and for eddy current effects. Then, nonbrain tissue was removed using FSL’s Brain Extraction Tool, and FA maps were obtained using the FMRIB Diffusion Toolbox. Tract-Based Spatial Statistics (TBSS) was used for voxel-wise statistical analysis of FA maps (Smith, 2002; Smith et al., 2006). Basically, within the TBSS protocol, nonlinear transforms were first applied using FNIRT to obtain FA images aligned to standard space and the resulting images were merged into single 4D image. Then, the mean of all FA images was fed into a skeletonization protocol obtaining the group mean FA skeleton. Finally, individual FA data were projected onto group skeleton.

DTI-based voxel-wise statistics on the FA maps were carried out using a permutation testing for nonparametric statistics using a GLM design. In a first GLM, we included the three main groups (CTR, AD, and FTLD), and we tested for differences between the three groups using age as a covariate. In a second set of analyses, we included individual biomarker values for each group, and subjects’ age. We tested for correlations between FA and each biomarker in the three groups, using age as a covariate. This procedure was performed separately for NFL, T-tau, Aβ, Ng, and 14-3-3.

2.8 | Disease-specific signatures and multiple regression approaches

We created diseases signature maps, obtained from the group comparison analyses, namely CThAD and CThFTD and FAAD and FAFTD, for the CTh and FA maps. In order to obtain descriptive overall patterns of atrophy we first compared FTLD and AD groups separately against the CTR. With the aim to explore differential alterations between FTLD and AD, we created the neuroimaging signatures for each disease by directly comparing the two groups (i.e., AD < FTLD and the FTLD<AD contrasts p < .05 corrected) for FA and CTh maps.

After creating these disease-specific signature maps, we obtained individual CTh and FA values for each signature across the entire sample of subjects. We tested multiple regression models in order to evaluate the predictive capabilities of the different biomarkers for each signature, using Akaike Information Criterion (AIC) stepwise algorithm in R (Sakamoto, Ishiguro, & Kitagawa, 1986). For that, we used a sample of N = 75 subjects, corresponding to those that had complete sets of MRI and CSF measures. Before multiple regression models, we evaluated pair-wise correlations of the different CSF biomarkers. We then created four separate models for predicting CThAD, CThFTD, FAAD, and FAFTD, with Aβ, T-tau, NFL, Ng, 14-3-3 levels and age as predictors. We used 90% confidence intervals obtained with bootstrapping algorithms to study the significance of the models and the relative importance of each predictor. In addition, we evaluated the multiple regression models corresponding to the hippocampal volume and the MMSE results.

3 | RESULTS

3.1 | Sample demographics, clinical data, and biomarkers

Demographic information, MMSE scores, and median levels of the biomarkers are shown in Table 1. In summary, we found a slightly

| TABLE 1 | Demographics, clinical data, and CSF-biomarker values |
| Group medians | Group comparisons |
| Gender (m/f) | CTR vs. AD | CTR vs. FTLD | AD vs. FTLD |
| CTR | AD | FTLD | p value | p value | p value |
| CTR vs. AD | .11 | .036 | .38 |
| CTR vs. FTLD | .19 | .0033 | .019 |
| AD vs. FTLD | N/A | N/A | 0.77 |

Note: Group summaries given as the median and the interquartile range of each measure. Pair-wise differences between groups are calculated using chi-square for gender or Kruskal–Wallis tests for the rest of the variables. Significant group-differences are highlighted in bold (Bonferroni-corrected p threshold = .0018).

Abbreviations: 14-3-3, 14-3-3 γ protein; Aβ, amyloid-beta protein 42; AD, Alzheimer’s disease; AU, arbitrary units; CTR, controls; FTLD, frontotemporal dementia; LP, lumbar puncture; MMSE, mini mental state examination; N/A, not-applicable; NFL, neurofilament light chain; Ng, neurogranine; P-tau, phosphorylated-tau, T-tau, total-tau.
greater proportion of females in the CTR group compared with the FTLD group. FTLD subjects were slightly older than CTR and AD groups \((p < .05)\). MMSE scores were lower in both AD and FTLD groups compared with CTR \((p < .05)\), but did not differ between AD and FTLD. We found lower A\(_{β}\)42 and higher T-tau and P-tau concentrations in AD compared to FTLD and CTR. Compared to CTR, NfL, and 14-3-3 were higher in both AD and FTLD, but in AD and FTLD comparison, NfL were higher in FTLD while 14-3-3 concentration was higher in AD. Ng levels in AD were higher than in CTR and FTLD (Table 1). Furthermore, we sub-analyzed the FTLD group compared to the other types (Table S1). We found significant correlation between several pairs of biomarkers, both in the whole sample or in the different clinical groups (Tables S2–S5).

3.2 | CTh results

3.2.1 | Group differences in CTh

We found reduced CTh in frontal and temporal areas in FTLD compared with CTR, and widespread CTh loss in AD (Figure 1). We use the map resulting from the AD < FTLD contrast to represent the CTh\(_{AD}\) signature, and the reverse contrast for the CTh\(_{FTLD}\) (see Figure 2a).

3.2.2 | Correlations between CTh and CSF biomarkers

In FTLD, NfL levels showed a significant negative correlation with CTh in a cluster located on the left hemisphere (cluster size = 15,667.98 mm\(^2\), cluster \(p = .0001\)), covering mainly frontal areas, including the pars opercularis, the pars triangularis, the middle and superior frontal, and the precentral (Figure 3) gyrus. We also found a negative correlation between CTh and T-tau levels across several bilateral frontal areas, mainly the superior frontal gyrus (Figure 3). In AD, no correlations were found between biomarker values and CTh.

3.3 | Hippocampal volumes

3.3.1 | Differences across diseases and correlations with biomarkers

We found reduced normalized hippocampal volume in AD and in FTLD compared with CTR \((p = 7.54 \times 10^{-10}\) and \(p = 4.51 \times 10^{-09}\), respectively). No differences in hippocampal volume were found between AD and FTLD \((p = .15)\).

When the three clinical groups were pulled together, normalized hippocampal volume showed correlations with A\(_{β}\)42 \((p = .01, r = .22\) age-corrected), T-tau \((p = .046; r = -.17)\), NfL \((p = .01, r = -.23)\), and Ng \((p = .046, r = -.20)\). We did not find any significant correlation between normalized hippocampal volumes and CSF biomarkers, when AD, FTLD, and CTR groups were studied separately (all \(p > .05\)).

3.4 | DTI results

3.4.1 | Group differences in FA

DTI analyses were performed with 112 subjects (49 AD, 23 FTLD, and 40 CTR) with available DTI data of good quality. When comparing FA maps across groups, we found patterns of significantly reduced FA both for AD and FTLD versus CTR. These decreases were found generally across the entire skeleton for both diseases, with predominance...
in frontal areas and the left hemisphere in FTLD. When the two disease groups were compared, we found greater alterations in the left hemisphere in FTLD, whereas we could not detect areas with lower FA in AD. The signature pattern for $\text{FA}_{\text{FTLD}}$ was defined as the difference between the AD > FTLD ($\text{FA}_{\text{FTLD}}$) maps, cut at $p < .05$ corrected (Figure 2a). The $\text{FA}_{\text{AD}}$ signature could not be defined due to the lack of significant differences in the AD > FTLD contrast.

### 3.4.2 FA and CSF biomarkers correlation analysis

In AD patients, we found a significant negative correlation between NfL values and FA in the forceps minor, the anterior thalamic radiation, the cingulum, the corticospinal tract, the uncinate fasciculus, the inferior longitudinal fasciculus, the inferior fronto-occipital fasciculus, and the temporal part of the superior longitudinal fasciculus. In FTLD patients, FA values in the forceps minor, the anterior thalamic radiation, cingulum, forceps minor, and the left superior longitudinal fasciculus correlated negatively with NfL (Figure 4). T-tau and 14-3-3 showed a negative correlation with FA in the forceps minor for the FTLD group. The remaining biomarkers ($\text{A} \beta$, Ng) did not yield any significant results.

### 3.4.3 Disease signatures and multiple regression results

The areas within each signature, representing different patterns of structural damage in AD and FTLD, are described previously and shown in Figure 2a.

In the multiple regression analysis, we found that $\text{A} \beta 42$ and 14-3-3 levels contributed to predict CTh levels within the CTh$_{\text{AD}}$ area, explaining 28% of its variance, whereas CTh values within the CTh$_{\text{FTLD}}$ area was better predicted by NfL and 14-3-3, explaining 29% of the variance. For FA values in $\text{FA}_{\text{FTLD}}$, NfL was the main predictor, explaining 56% of the variance. No regression analysis was performed for FA values in AD because any regions survived the statistical threshold in AD > FTLD contrast. Ng levels were not predictive in any of the models (Table 2).

In addition to the disease signature patterns, we created models for the hippocampus volumes (using the normalized bilateral volume) and for the MMSE scores. We found that $\text{A} \beta 42$, NfL, and AGE were the factors that better explained the hippocampal volume (28% of variance), whereas NfL, 14-3-3, and age, predicted the MMSE score (28% variance) through the entire sample.
For each model, we calculated the relative importance of each predictor and we found that NfL had the highest impact in CThFTLD (89%) and it was the only variable depicted for FAFTLD, whereas Aβ had the highest importance for CThAD (64%). The most important predictors for the hippocampal volume and for MMSE were NfL and 14-3-3, respectively (Figure 2b).

**DISCUSSION**

We performed a cross-sectional study of structural GM and WM alterations and their relationship with CSF biomarkers in early-onset AD and FTLD. Differential patterns of brain loss and CSF biomarkers profiles were found for both diseases. For the AD signatures, we found that, in addition to Aβ, 14-3-3 was the only neurodegeneration marker that significantly contributed to CTh levels variation, whereas T-tau contributed to FA levels. For FTLD signatures, NfL and 14-3-3 were the main contributors to both CTh and FA values.

In our cohort, as expected, EO AD patients showed lower Aβ and higher T-tau and P-tau CSF concentrations compared to FTLD and controls (Mattson, 2017). NfL concentrations were higher in both diseases compared with CTR, and in FTLD compared to AD, in concordance with previous publications (Ljubenkov et al., 2018; McFerrin et al., 2017; Sjögren et al., 2000). Ng in AD were higher than controls and FTLD, but not significant differences were found in FTLD with respect to CTR (Gaetani et al., 2019; Wellington et al., 2016; Portelius et al., 2018; Lista, Toschi, Baldacci, et al., 2017). There are few data about 14-3-3 levels in nonprion neurodegenerative disorders, in our cohort, 14-3-3 levels were increased in AD and FTLD compared with CTR and in AD compared with FTLD (Burkhard et al., 2001).

We found cortical and subcortical (hippocampus) GM loss in both AD and FTLD compared with controls. In general, the atrophy pattern was more widespread in AD and presented a fronto-temporal pre-dominance in FTLD in line with previous publications (Möller et al., 2015; Rabinovici et al., 2007). We also found WM integrity loss in both diseases, greater in FTLD than AD. These findings are similar to previous studies evaluating the structural connectivity in neurodegenerative dementias that have suggested more WM damage in FTLD compared to AD, especially in frontal and temporal regions (Canu et al., 2017; Möller et al., 2015; Ossenkoppele et al., 2015; Zhang, Schuff, Du, et al., 2009).

### TABLE 2

|           | Aβ   | T-tau | NfL | Ng  | 14-3-3 | AGE | R2   | Variance explained by model |
|-----------|------|-------|-----|-----|--------|-----|------|----------------------------|
| CThAD     | 0.639 [0.19, 0.97] | 0.361 [0.033, 0.807] | 0.28 | 28% |
| FAAD      | N/A  | N/A   | N/A | N/A | N/A    | N/A | N/A |
| CThFTLD   | 0.890 [0.52, 0.99] | 0.110 [0.001, 0.48] | 0.31 | 29% |
| FAFTLD    | 1    | 0.56  | 0.28 | 28% |
| HV        | 0.365 [0.05, 0.69] | 0.398 [0.039, 0.865] | 0.237 [0.004, 0.64] | 0.28 | 28% |
| MMSE      | 0.117 [0.0004, 0.58] | 0.723 [0.22, 0.95] | 0.160 [0.012, 0.41] | 0.28 | 28% |

Note: These data show results of a multiple regression models. Coefficients are normalized to show relative contribution of each variable. Abbreviations: 14-3-3, 14-3-3 protein; Aβ, amyloid-beta protein 42; CThAD/CThFTLD, mean cortical thickness values within the AD/FTD signatures; FAAD/FAFTLD, mean FA values within the defined FA/AD signatures; HV, hippocampal volume; MMSE, mini mental state examination; N/A, not applicable; NfL, neurofilament light chain; Ng, neurogranine; P-tau, phosphorylated-tau, T-tau, total-tau.
In the multivariate analysis, we found that AD and FTLD neuroimaging signatures were differentially influenced by CSF biomarkers. For AD, Aβ was the biomarker that most contributed to CTh values in AD signature. Unexpectedly 14-3-3 resulted a significant predictor of CTh values while other neurodegeneration markers as T-tau, NfL, and Ng did not. Previous studies have analyzed the contribution of Aβ and T-tau to structural changes in AD (Blennow et al., 2019; Li et al., 2014; Tosun, Schuff, Shaw, et al., 2011). The relevant contribution of Aβ in the CTh AD signature in the present study is plausible given its main role in AD pathophysiology. A plateau effect of the Aβ load in symptomatic stages of the disease has been defined, suggesting that brain atrophy might be more related to tau spread rather than amyloid burden (Blennow & Zetterberg, 2018). In contrast, our results indicate that Aβ levels contribute to the typical AD structural changes observed. Even if this effect might be driven by the fact that low Aβ levels are a hallmark to all the AD subjects included, we believe that it might also suggest an effect in early symptomatic stages. However, we cannot claim that the correlation found between Aβ and cortical brain atrophy in our cohort demonstrates a causal relationship between them. Overall, this finding highlights the complex relationships among different biomarkers through the AD pathology. Moreover, in our cohort, 14-3-3 levels showed a strong correlation with T-tau levels both in the whole group and in the different clinical subgroups. This could suggest that the effect of T-tau observed in other studies could be related to the 14-3-3 effect we observed in this study, while here the strong correlation observed could cancel the effect of T-tau in the regression model. Unfortunately, we could not study the AD signature because we did not find any brain area in which FA was significantly different in AD compared with FTLD. This finding is in agreement with previously published data and it could be attributed to a more intense WM damage in FTLD (Möller et al., 2015).

Both CTh and FA values within the FTLD signature were mostly explained by NfL levels, although 14-3-3 levels also contributed. NfL values were associated CTh and FA values in the left frontal and temporal regions in FTLD. These data support that NfL is a neurodegeneration marker strongly related to FTLD (Ljubenkov et al., 2018). These findings are also consistent with previous studies in FTLD patients that reported correlations between brain structure and NfL concentration especially in frontotemporal areas, with predominance in the left hemisphere (Rohrer et al., 2016; Scherling et al., 2014). The relation of NfL with WM changes, beyond the GM loss, is plausible as NfL is an axonal protein (Ossenkoppele et al., 2015). Although we believe that studying the differences through the FTLD spectrum could be of interest, in the present study, the sample was not big enough to perform this approach for the different clinical variants separately.

14-3-3 was also the main factor in MMSE, supporting a role as a nondisease specific marker of neurodegeneration. Regarding hippocamal volume, we found that Aβ and NfL accounted almost equally models suggesting both CSF biomarkers could contribute to the subcortical atrophy, as suggested previously (Idland et al., 2017).

Ng was the only CSF biomarker that did not influence any model, despite being altered in AD subjects even if has been suggested to be a specific biomarker of AD. Although our data further support previously reported elevated CSF Ng concentrations in AD compared with FTLD and controls, it did not reach relevance enough to outstanding in the AD statistical model. These results are in line with a recent publication that reported that Ng did not show a diagnostic added value to the classic basic AD biomarkers in terms of diagnostic accuracy (Lista et al., 2017).

We should acknowledge several limitations in this study. First, the relatively small sample size, especially in the FTLD group. In this sense, the inclusion of different clinical FTLD variants can lead to some variability within the FTLD group, but which in turn reflects the heterogeneity of the FTLD itself. We also acknowledge that the fact that the maps obtained from the groups are then used in the analysis with biomarkers that also differ between groups could introduce some circularity. However, we think that the goal of evaluating which biomarkers better explained these structural changes is valid as we use multiple regression models and the relevance of the result is the magnitude of the effect of AD core biomarkers compared to other biomarkers. Further studies in larger cohorts are needed to confirm and expand these data.

In conclusion, our study suggests that biochemical markers might contribute differently to structural (CTh and FA) changes typical of AD and these results support the complexity of the relationship between CSF biomarker and structural brain changes in these diseases.

ACKNOWLEDGMENTS
The authors thank patients, their relatives, and healthy controls for their participation in the research. This work was supported by Spanish Ministry of Economy and Competitiveness-Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, “Una manera de hacer Europa” [PI14/00282 to Dr. A. Lidá], PERIS 2016–2020 Departament de Salut de la Generalitat de Catalunya [SLT002/16/00408 to Dr. Sanchez-Valle] and Fundació Marató de TV3, Barcelona, Spain [Grant 20143810 to Dr. Sanchez-Valle] and CERCA Programme/Generalitat de Catalunya. Dr. Neus Falgàs received funding from Hospital Clinic Barcelona [Ajut Josep Font]. Dr. Anna Antonell (PERIS 2016–2020 SLT002/16/00329) and Dr. Albert Lladó (PERIS SLT008/18/00061) received funding from Departament de Salut de la Generalitat de Catalunya. Dr. Sergi Borrego-Ecija is a recipient of a Rio Hortega grant and Dr. Oscar Ramos of a PFIS grant, from the ISCIII, Spain. H.Z. is a Wallenberg Academy Fellow supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGFG-720931) and the UK Dementia Research Institute at UCL. K.B. holds the Torsten Söderberg Professorship in Medicine at the Royal Swedish Academy of Sciences, and is supported by the Swedish Research Council (#2017-00915), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), and a grant (#ALFGFBG-715986) from the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement.
CONFLICT OF INTEREST

H.Z. has served at scientific advisory boards of Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Biogen and Alzecure, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (all outside the submitted work). K.B. has served as a consultant or at advisory boards for Alector, Biogen, CogRx, Lilly, MagQu, Novartis, and Roche Diagnostics, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg, all unrelated to the work presented in this article. The other authors have nothing to disclose.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Neus Falgàs https://orcid.org/0000-0002-3404-2765
Roser Sala-Llonch https://orcid.org/0000-0003-3576-0475
Anna Antonell https://orcid.org/0000-0002-3286-8459
Mircea Balasa https://orcid.org/0000-0002-1795-4228
Sergi Borrega-Ecija https://orcid.org/0000-0003-2557-0010
Oscar Ramos-Campoy https://orcid.org/0000-0003-3922-6827
Josep Maria Augé https://orcid.org/0000-0001-6383-7308
Magdalena Castellví https://orcid.org/0000-0001-8769-9288
Adrià Tort-Merino https://orcid.org/0000-0002-5646-0482
Jaume Olives https://orcid.org/0000-0003-1961-4830
Henrik Zetterberg https://orcid.org/0000-0003-3930-4354
Núria Bargalló https://orcid.org/0000-0002-4671-6763
Albert Lladó https://orcid.org/0000-0002-5066-4150
Raquel Sánchez-Valle https://orcid.org/0000-0001-7750-896X

REFERENCES

Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman H.H., Fox, N.C., Phelps, C.H., (2012). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 7, 270–279.
Alcolea, D., Vilaplana, E., Suárez-Calvet, M., Illán-Gala, I., Blesa, R., Clarimón, J., ... Lleó, A. (2017). CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology, 89(2), 178–188.
Blennow, K., Díaz-Lucena, D., Zetterberg, H., Villar-Piqué, A., Karch, A., Vidal, E., ... Llorens, F. (2019). CSF neurogranin as a neuronal damage marker in CJD: A comparative study with AD. Journal of Neurology, Neurosurgery, and Psychiatry, 90(8), 846–853.
Blennow, K., & Zetterberg, H. (2018). Biomarkers for Alzheimer’s disease: Current status and prospects for the future. Journal of Internal Medicine, 284(6), 643–663.
Burghard, P. R., Sanchez, J. C., Landis, T., Hochstrasser, D.S. (2001). CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology, 56(11), 1528–1533.
Canu, E., Agosta, F., Mandić-Stojmenović, G., Stojković, T., Stefanova, E., Inuggi, A., ... Filipp, M. (2017). Multiparametric MRI to distinguish early onset Alzheimer’s disease and behavioural variant of frontotemporal dementia. Neurorimage: Clinical, 15, 428–438.
Chohan, G., Pennington, C., Mackenzie, J. M., Andrews, M., Everington, D., Will, R. G., ... Green, A. J. E. (2010). The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: A 10-year review. Journal of Neurology, Neurosurgery, and Psychiatry, 81(11), 1243–1248.
Dale, A. M., Fischl, B., & Sereno, M. I. (1999). Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage, 9(2), 179–194.
Falgàs, N., Tort-Merino, A., Balasa, M., Borrega-Écija, S., Castellví, M., Olives, J., ... Liadó, A. (2019). Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment. European Journal of Neurology, 26(8), 1098–1104.
Fischl, B., & Dale, A. M. (2000). Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proceedings of the National Academy of Sciences of the United States of America, 97(20), 11050–11155.
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Hasegawa, C., ... Dale, A. M. (2002). Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron, 33(3), 341–355.
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., Zetterberg, H. (2019). Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery, and Psychiatry, 90 (8), 878–881.
Garre-Olmo, J., Genis Batlle, D., del Mar Fernández, M., Marquez, D., Huélamo, R.E., Casadevall, T., ... López-Pousa, S. (2010). Registry of dementia of Girona study group (ReDeGi study group). Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology, 14, 1249–1255.
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., ... Grossman, M. (2011). Classification of primary progressive aphasia and its variants. Neurology, 76, 1006–1014.
Idliand, A. V., Sala-Llonch, R., Borza, T., Watne, L. O., Wyller, T. B., Brakhus, A., ... Fjell, A. M. (2017). CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. Neurobiology of Aging, 49, 138–144.
Koedam, E. L., Lauffer, V., van der Vlies, A. E., van der Flier, W.M., Scheltens, P., Pijnenburg, Y.A. (2010). Early-versus late-onset Alzheimer’s disease: More than age alone. Journal of Alzheimer’s Disease, 19, 1401–1409.
Kvartasberg, H., Duits, F. H., Ingelsson, M., Andreassen, N., Øhrfelt, A., Andersson, K., ... Blennow, K. (2015). Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodomal Alzheimer’s disease. Alzheimers Dement, 11, 1180–1190.
Li, X., Li, T. Q., Andreasen, N., Wiberg, M. K., Westman, E., & Wahlund, L. O. (2014). The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer’s disease. Journal of Internal Medicine, 275(4), 418–427.
List, A., Noten, B., Baldauf, M., Deikman, L., Kildian, J., ... Jung, H. (2015). Alzheimer precision medicine initiative (APMI), Cerebrospinal fluid Neo- granin as a biomarker of neurodegenerative diseases: A cross-sectional study. Journal of Alzheimer’s Disease, 59(4), 1327–1334.
Ljubenkov, P. A., Gaetani, L., Chohan, G., Pennington, C., Mackenzie, J. M., Andrews, M., Everington, D., Will, R. G., Green, A. J. E. (2010). The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: A 10-year review. Journal of Neurology, Neurosurgery, and Psychiatry, 81(11), 1243–1248.
McFerrin, M. B., Chi, X., Cutter, G., Yacoubian, T.A. (2017). Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Levy body or...
Alzheimer pathology. Annals of Clinical and Translational Neurology, 4(7), 466–477.

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., ... Phelps, C.H. (2011). The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 7, 263–269.

Mölter, C., Hafkemeijer, A., Pijnenburg, Y. A., Rombouts, S.B, Grond, J., Dopper, E., ... van der Flier, W.M. (2015). Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTLD: A two-center study. Neuroimage Clin, 9, 418–429.

Moreno, F., Sala-Llonch, R., Barandiaran, M., Sánchez-Valle, R., Estanga, A., Molle, C., Hafkemeijer, A., Pijnenburg, Y.A., Romboouts, S.B., Gron, J., Dopper, E., ... Wellington, H., Paterson, R. W., Portelius, E., Törnqvist, U., Blennow, K. (2013). Distinctive age-related temporal cortical thinning in asymptomatic granulin gene mutation carriers. Neurobiology of Aging, 34(5), 1462–1468.

Olsson, B., Portelius, E., Cullen, N. C., Sandellius, A., Zetterberg, H., Andreasson, U., ... Blennow, K. (2019). Association of Cerebrospinal Fluid Neurofilament Light Protein Levels with Cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurology, 76(3), 318–325.

Ossenkoppele, R., Mattsson, N., Teunissen, C. E., Barkhof, F., Pijnenburg, Y., Scheltens, P., ... Rabinovici, G. D. (2015). Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 36(8), 2340–2347.

Pegueroles, J., Vilaplana, E., Montal, V., Sampedo, F., Alcolea, D., Carmona-Iragui, M., ... Alzheimer’s Disease Neuroimaging Initiative. (2017). Alzheimer’s Disease Neuroimaging Initiative. Longitudinal brain structural changes in preclinical Alzheimer’s disease. Alzheimers Dement, 13(5), 499–509.

Portelius, E., Olsson, B., Hägglund, K., Cullen, N. C., Kvartshberg, H., Andreasson, U., ... Blennow, K. (2018). Cerebrospinal fluid neurogranin concentration in neurodegeneration: Relation to clinical phenotypes and neuropathology. Acta Neuropathologica, 136(3), 363–376.

Rabinovici, G. D., Seeley, W. W., Kim, E. J., Gorno-Tempini, M. L., Rascovsky, K., Pagliaro, T. A., ... Rosen, H. J. (2007). DistinctMRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. American Journal of Alzheimer’s Disease and Other Dementias, 22(6), 474–488.

Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhas, J., ... Miller, B. L. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 134, 2456–2477.

Rohrer, J. D., Woollacott, I. O. C., Dick, K. M., Brotherhood, E., Gordon, E., Fellows, A., ... Zetterberg, H. (2016). Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology, 87, 1329–1336.

Sakamoto, Y., Ishiguro, M., & Kitagawa, G. (1986). Akaike information criterion statistics. Netherlands: D. Reidel Publishing Company.